Company intelligence / Profile preview

AlgoTherapeutix

Suresnes, Paris, Francelife-sciences-europe.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AlgoTherapeutix completed a Phase 2 "ACT" trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy with 276 patients. The trial showed encouraging efficacy signals, particularly at the higher concentration of 15%, but a high placebo effect prevented overall statistical significance. In post-hoc analysis of low-placebo sites, ATX01 15% showed statistically significant superiority to placebo on most primary and secondary endpoints. The company is considering further development with modified trial designs to minimize placebo effects.

Therapeutic areas: CardiovascularNeurology
Modalities: Small moleculestopical formulations
Industry: Biotech

Drug pipeline

1 asset

ATX01

Phase 2

Indications: Chemotherapy-induced peripheral neuropathy, Erythromelalgia

Beyond the preview

Go deeper on AlgoTherapeutix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlgoTherapeutix.

Explore the full profile